

ASX ANNOUNCEMENT

2 August 2023

LGP's Desert Flame granted Polish Marketing Authorisation



Highlights:

- LGP's Desert Flame high THC medicinal cannabis flower product has been granted a Marketing Authorisation in Poland
- Marketing Authorisations are the sole pathway for supplying medicinal cannabis in Poland
- LGP's distribution partner Medezin will hold the Marketing Authorisation and distribute the product on a white-label basis in Poland
- Medezin is a subsidiary of the Pelion Group SA, the largest operator in the Polish and Lithuanian healthcare sectors
- The first shipment is scheduled for October 2023
- With a predicted compound annual growth rate of 16%, LGP regards Poland as a highly prospective medicinal cannabis market

Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") is pleased to announce its Desert Flame high THC (20%) medicinal cannabis flower product has been granted a Marketing Authorisation in Poland. The Company is scheduled to ship its first product from Australia in October 2023.

Marketing Authorisations are the sole pathway for the supply of medicinal cannabis products in Poland. There are currently ten Marketing Authorisations for cannabis flower products with a THC content in the range of 18-22%, with current wholesale medicinal cannabis flower prices ranging between €7.50 to €9.50 per gram and retail prices from between €11 - €15 per gram.

LGP's distribution partner, Medezin S.p. z.o.o. ("**Medezin**"), will hold the Marketing Authorisation and distribute the product on a white-label basis during the term of the parties' distribution agreement. Medezin is a highly experienced and large-scale pharmaceutical distributor and a wholly owned subsidiary of Pelion SA, the largest operator in the Polish and Lithuanian healthcare sectors: see ASX released dated 17 June 2021 for further details.

Since 2021, LGP has invested time and resources developing its product dossier expertise and was responsible for preparing and submitting the Marketing Authorisation application for the product. Today, the Company stands well positioned to apply to register additional products in Poland and other jurisdictions with similarly high barriers to entry.

With a population of 38 million, an import only supply regime¹, general practitioner (GP) prescribing capability, no restrictions on the conditions treatable with cannabis, and a predicted compound annual growth rate (CAGR) of 16%², LGP regards Poland as another highly prospective new medicinal cannabis market in Europe alongside France and Italy. The Company believes the Marketing Authorization continues to confirm the advantages of developing a robust, export-led sales strategy as well as LGP's status as a significant global exporter of medicinal cannabis.



Pelion SA Group

Pelion SA is the largest company in the Polish and Lithuanian healthcare sector, with nearly 10 billion PLN (~A\$3.5 billion) in annual revenue and a 30-year operating history covering all areas of pharmaceutical distribution.

Medezin specializes in services to local and offshore pharmaceutical manufacturers and distributors, helping them with market access, importation, distribution and logistics, medical marketing or repackaging.

Medezin is a 100% owned subsidiary of Polska Grupa Farmaceutyczna S.A., one of the three leading full-range wholesalers in Poland with a 20% share of domestic deliveries to pharmacies. Its sister company Urtica is the largest distributor of drugs for inpatient treatment in hospitals while another sister company, DOZ SA, manages over 1000 pharmacies with its doz.pl platform the largest e-commerce platform in Poland.

ENDS
BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to be "Alistair Warren".

Alistair Warren
Company Secretary

¹<https://www.euromonitor.com/article/cannabis-in-poland-big-opportunities-come-with-risks>

²<https://www.statista.com/outlook/hmo/cannabis/medical-cannabis/poland>



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +618 6280 0050

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +618 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, with its Danish facility being one of the largest GMP medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp